RT Journal Article
SR Electronic
T1 Inflammatory Bowel Disease in Juvenile Idiopathic Arthritis Patients Treated with Biologics
JF The Journal of Rheumatology
JO J Rheumatol
FD The Journal of Rheumatology
SP jrheum.140472
DO 10.3899/jrheum.140472
A1 Deborah Barthel
A1 Gerd Ganser
A1 Rolf-Michael Kuester
A1 Nils Onken
A1 Kirsten Minden
A1 Hermann Josef  Girschick
A1 Anton Hospach
A1 Gerd Horneff
YR 2015
UL http://www.jrheum.org/content/early/2015/09/10/jrheum.140472.abstract
AB Objective Evolving inflammatory bowel disease (IBD) is a matter of interest in patients with juvenile idiopathic arthritis (JIA) and might be associated with JIA therapy. Methods Data from the German biologics registry (Biologika in der Kinderrheumatologie; BiKeR) from 2001 to 2013 were analyzed. Results There were 3071 patients with 8389 patient-years (PY) of observation followed. IBD was diagnosed in 11 patients, 8 with Crohn disease and 3 with ulcerative colitis. IBD incidence in patients with JIA was 1.31/1000 PY and higher than published IBD incidences in pediatric populations. Compared with the total BiKeR cohort, patients with IBD more commonly had enthesitis-related arthritis, extended oligoarthritis, psoriatic arthritis, and also rheumatoid factor (RF)-negative polyarthritis. No IBD occurred in patients with systemic JIA or RF-positive polyarthritis. In patients treated with methotrexate (MTX), the IBD incidence was significantly lower compared with patients not treated with MTX. Etanercept (ETN) monotherapy, but not the combination of ETN and MTX, was associated with an increased incidence of IBD. Conclusion Incidence of IBD in patients with JIA is higher than in the population. MTX turned out to be protective, even in combination with ETN.